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Contrary to the conventional assumption that damaged
organs are repaired only by migration and prolifera-
tion of local cells, accumulating evidence suggests that
bone marrow-derived progenitor cells are mobilized
into the systemic circulation and recruited to the site of
tissue regeneration. In vascular lesions, recent reports
documented that bone marrow-derived endothelial
progenitor cells (EPCs) significantly contributed to neo-
vascularization and re-endothelialization after acute
vascular injury1. It was demonstrated that transplan-
tation of autologous EPCs or unfractionated bone
marrow cells is effective for the treatment of ischemic
cardiovascular disease in several animal and clinical
studies2. Consequently, bone marrow-derived progeni-
tor cells seem to be a useful tool for vascular diseases.
On the other hand, others suggested that bone marrow
cells or circulating progenitor cells participate not only
in repair of vascular homeostasis, but also in the
pathogenesis of various diseases. In this article, we
describe our recent findings and those of others that
circulating progenitor cells contribute to vascular repair,
new vessel formation, and also lesion formation3–5. In
addition, we suggest that putative vascular progenitor
cells could be used as therapeutic and diagnostic tools,
but several issues need to be clarified before these
cells are widely used as an established strategy to treat
patients with cardiovascular diseases.
Origin of Smooth Muscle Cells in 
Vascular Lesions
For vascular diseases, pronounced accumulation of
smooth muscle cells (SMCs) plays a major role in the
pathogenesis. In atherosclerotic plaques, SMCs prolifer-
ate and synthesize extracellular matrix, contributing
to lesion mass. In clinical treatment, percutaneous
coronary interventions have widely been recognized
to be the most standard therapy for coronary stenosis.
However, postangioplasty restenosis has been observed
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at a constant rate after treatment and it worsens the
prognosis. Moreover, SMC hyperplasia is a major cause
of post coronary bypass surgery occlusion6 and graft
vasculopathy after transplantation7. Therefore, much
effort has been taken to understand the molecular
pathways that regulate SMC behavior. It has been
hypothesized that SMCs in media dedifferentiate and
migrate to the subendothelial space, proliferate, and
contribute to atherogenesis in the process of athero-
sclerotic lesion formation8. In the same way, it has been
assumed that all of the neointimal cells in postangio-
plasty restenosis and graft vasculopathy are derived
from local medial SMCs. Thus, an extensive number 
of pharmacologic and gene therapies have been
focused on the suppression of medial SMC migration
and proliferation.
However, there are several observations that chal-
lenge the conventional hypothesis that all SMCs migrate
from the media to the intimal lesion. First, very few papers
have documented SMC migration across the internal
elastic lamina from the tunica media to the subendothe-
lial layer. On the other hand, many studies have shown
that blood cells attach to the luminal side of the injured
artery prior to the development of neointimal hyperpla-
sia9. Second, it has been observed that SMCs in the media
disappeared after severe injury caused by severe dam-
age; neointima can grow rapidly after the injury9. In this
study, it was also noted that neointimal cells were nega-
tive for mature SMC markers like myosin heavy chain,
calponin, and h-caldesmon. The cells appeared to be
rather hematopoietic at 1 week after injury. Third, many
studies have reported that SMC hyperplasia can be
prevented by blocking chemokines or adhesion mole-
cules10,11, which play a crucial role in recruiting blood
cells. But these factors have little or no effect on the
migration and proliferation of SMCs10. Fourth, neointi-
mal SMCs express hematopoietic markers like FK506-
binding protein 12, which is an interferon regulatory
factor, and proinflammatory proteins12. These obser-
vations suggest that some of the neointimal SMCs
might be derived from blood cells rather than medial
cells. Recent studies support this hypothesis with several
animal models3–5,13.
Graft Vasculopathy
Graft vasculopathy is considered to be a robust form of
atherosclerosis7. First, we reported the contribution of
bone marrow cells to vascular lesions in graft vasculopa-
thy4. In this study, heterotopic cardiac transplantation
was performed between wild-type and ROSA mice,
which express LacZ in all tissues3,5. We transplanted the
heart of wild-type mice to the abdominal aorta of recip-
ient LacZ mice. Four weeks after transplantation, the
lumen of coronary arteries of the transplanted heart
and their smaller branches and arterioles narrowed due
to concentric neointimal hyperplasia. The majority of
the neointima were composed of recipient cells express-
ing LacZ. It was also observed that some of the medial
SMCs, as well as endothelial cells (ECs), had been replaced
by recipient cells. Immunofluorescence studies showed
that LacZ-positive cells in the neointima expressed vari-
ous markers for SMC, including myosin heavy chain,
calponin, h-caldesmon, and α-smooth muscle actin
(α-SMA)3. Conversely, when LacZ-positive hearts were
transplanted into wild-type mice, LacZ-negative neoin-
tima developed on the LacZ-positive coronary arteries.
Furthermore, in situ hybridization of the allografts from
female to male mice showed that most of the neointi-
mal cells corresponded to cells from the recipients5.
These results indicated that the majority of the neoin-
timal cells were derived from the recipient cells, but not
from the medial cells of donor origin. Consistent with
these observations, others have independently reported
that recipient cells are a major source of graft vascu-
lopathy in aortic transplantation models14–17. Moreover,
it was reported that most of the neointimal cells and
ECs were derived from recipients in human transplant-
associated arteriosclerosis after renal transplantation18.
Next, to identify the potential source of recipient
cells that contribute to allograft vasculopathy, bone
marrow transplantation (BMT) was performed from LacZ
mice to wild-type mice (BMTLacZWild mice). These mice
expressed LacZ protein only in the reconstituted bone
marrow cells. After 4–8 weeks, wild-type hearts were
transplanted heterotropically into the BMTLacZWild
mice. Four weeks after cardiac transplantation, most of
the neointimal cells (82.5 ± 11.5%) were LacZ positive.
Similarly, when wild-type hearts were transplanted into
wild-type mice whose bone marrow had been recon-
stituted with that of transgenic mice that express green
fluorescent protein (GFP mice) (BMTGFPWild mice)3, it
was observed that GFP-positive cells accumulated on the
luminal side of the graft coronary arteries. Immuno-
fluorescent study showed that some of the GFP-positive
cells in graft vasculopathy expressed α-SMA. These
results indicate that recipient bone marrow might be
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the source of the recipient cells, which were observed
in the neointima of transplanted graft (Figure 1).
Bone Marrow Cells Contribute to 
Lesion Formation After Mechanical 
Vascular Injury
Bone marrow cells can also contribute to the patho-
genesis of lesion formation after mechanical vascular
injury3,4,13. For these experiments, BMT was performed
from LacZ mice to wild-type mice (BMTLacZWild mice).
Four to 8 weeks after BMT, a large wire was inserted
into the femoral artery of BMTLacZWild mice, leading
to complete endothelial denudation and marked
enlargement of the vascular lumen9. The cellularity of
the medial layer decreased as a result of acute onset of
SMC apoptosis. One week after the injury, the artery
remained dilated, and LacZ-positive cells were detected
at the luminal side of the injured vessels. At this point,
LacZ-positive cells did not express a marker for SMCs
(α-SMA) or for ECs (CD31). The dilated lumen narrowed
gradually due to neointimal hyperplasia that comprised
LacZ-positive SMCs3,13. Four weeks after the wire injury,
a significant amount of neointimal (63.0 ± 9.3%) and
medial cells (45.9 ± 6.9%) was LacZ positive as deter-
mined by X-gal staining (Figure 2). Immunofluorescence
double staining documented that some bone marrow-
derived LacZ-positive cells in the neointimal lesions
expressed α-SMA or CD3113. These results indicated that
bone marrow cells might give rise to vascular cells, fol-
lowing mechanical endovascular injury.
Numerous reports have demonstrated that neoin-
timal cells are heterogeneous and that SMCs in vascular
lesions are composed of cells of diverse origin13. It has
been shown that the cellular constituents of a lesion
differ depending on the type of vascular injury13. In this
study, three distinct types of mechanical injuries were
compared in the same mouse model whose bone mar-
row had been reconstituted with that of GFP or LacZ
mice13. After wire-mediated endovascular injury, a sig-
nificant number of the neointimal and medial cells were
derived from bone marrow. In contrast, marker-positive
cells were seldom detected in the lesion induced by
perivascular cuff placement. Only a few bone marrow-













Figure 1. Contribution of bone marrow-derived progenitor cells to transplant-associated atherosclerosis. (A) Heterotopic heart
transplantation is performed with marker-positive mice and hearts from wild-type mice. The neointima of allograft coronary
arteries is composed of marker-positive cells. (B) Next, cardiac allograft transplantation is performed into BMTLacZwild mice.
A large amount of marker-positive cells is detected in the neointima. It suggests that bone marrow-derived progenitor cells
might contribute to graft vasculopathy. Small arrows indicate internal elastic laminae. BMT = bone marrow transplantation.
Reproduced with permission from the Nature Publishing Company.
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following ligation of the common carotid artery. These
findings suggest that the type of injury is crucial for the
recruitment of bone marrow-derived cells for tissue
remodeling and that bone marrow cells substantially
contribute to lesion formation only when arteries are
subjected to severe injury13. Therefore, it was predicted
that circulating progenitors would only contribute to
vascular remodeling in humans when arteries are sub-
jected to severe injury. Consistent with this notion, an
analysis of sex-mismatched bone marrow transplant
human subjects showed that the recruitment of bone
marrow-derived SMCs was observed in atherosclerotic
lesions of the recipient arteries, but not in the undis-
eased segments19.
Bone Marrow might be the Origin of
SMC-like Cells in Atherosclerotic Plaques
To evaluate the potential source of SMCs observed in
atherosclerotic plaques, the bone marrow of 8-week-old
apolipoprotein E (ApoE)−/− mice was replaced with that
of GFP mice (BMTGFPApoE−/− mice) or LacZ mice
(BMTLacZApoE−/− mice)3. The recipient mice were kept
with a western type diet for 8 weeks starting at 4 weeks
after BMT20. It was observed that bone marrow-derived
marker-positive cells accumulated in the atherosclerotic
plaques that developed in the aorta of BMTGFPApoE−/−
mice. A significant amount (42.5 ± 8.3%) of α-SMA-pos-
itive cells in the lesion was GFP positive. Similarly, in
the atherosclerotic lesions of BMTLacZApoE−/− mice, the
majority of the α-SMA-positive cells (58.2 ± 8.6%)
expressed LacZ detected by X-gal staining (Figure 3).
Therefore, these results suggest that some of the SMC-
like cells observed in hyperlipidemia-induced athero-
sclerotic plaques might originate from bone marrow.
Bone Marrow-derived Progenitor 
Cells in Angiogenesis
In the human adult, angiogenesis is associated not only
with tissue growth, but also with wound healing and
reproductive functions. Angiogenesis is also implicated
in the pathogenesis of a variety of disorders including
diabetic retinopathies, tumors21, rheumatoid arthritis,
psoriasis22, and atherosclerosis23,24. Therefore, much
effort has gone into understanding the molecular path-
ways that regulate angiogenesis and to the development
of new strategies to treat refractory diseases targeting
angiogenesis21. It is believed that new vessel formation








Wild-type mice LacZ mice
Figure 2. Contribution of bone marrow cells to lesion formation after mechanical injury. The femoral arteries of BMTLacZwild
mice are injured by inserting a large wire. In the mice, circulating cells are replaced by LacZ-positive cells. The injured arteries
are harvested after 4 weeks and stained with X-gal. A significant number of LacZ-positive cells are detected in the neointima
and the media. Arrows indicate internal elastic lamina. Arrowheads indicate external elastic lamina. BMT = bone marrow
transplantation.
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degrade the basement membrane of the vessel wall,
migrate, and proliferate. In 1997, the existence of EPCs
in peripheral blood was first reported by Asahara et al.1,
which was followed by numerous studies that described
the diagnostic and therapeutic applications of EPCs.
After that, accumulating evidence about EPCs was pro-
vided by many studies1,25. EPCs were successfully incor-
porated into the site of angiogenesis under physiologic
and pathologic angiogenesis26. Moreover, EPCs were
shown to contribute to the repair of endothelium and
the maintenance of vascular homeostasis3,18.
On the other hand, EPCs are also suggested to con-
tribute to tumor-associated angiogenesis27, injury-
associated retinal angiogenesis28, and formation of
microvessels in transplant arteriosclerosis29. Thus, there
is a possibility that transplantation of bone marrow-
derived progenitors augments disease-associated unfa-
vorable angiogenesis.
Fractions of Bone Marrow Cells that
Contribute to Vascular Remodeling
Bone marrow includes pluripotent cells. Pluripotent
cells are classified as hematopoietic stem cells (HSCs)
and mesenchymal stem cells. Conventionally, HSCs were
assumed to give rise only to hematopoietic lineage30.
Recent reports indicated that they might have the
broader potential to differentiate into various cell types,
such as epithelial cells31, cardiomyocytes32, and hepa-
tocytes33. In our previous study, to identify the bone
marrow cells that have the potential to generate vas-
cular cells, we isolated a HSC-enriched fraction (c-Kit+,
Sca-1+, Lin−) (KSL fraction) of bone marrow cells of LacZ
mice by fluorescence-activated cell sorting3 and injected
3,000 cells into lethally irradiated wild-type mice. Four
weeks after bone marrow reconstitution, the femoral
artery of the recipient mice was mechanically injured
with a large wire34. At 4 weeks after the injury, the
neointima and the media contained many LacZ-positive
cells3, and some of them expressed α-SMA. LacZ-positive
cells were also found to contribute to endothelial regen-
eration3. These findings suggest that the KSL fraction
of bone marrow cells might have the potential to dif-
ferentiate into both SMCs and ECs that participate in
vascular remodeling.
In contrast, Wagers et al. extensively analyzed organs
of wild-type mice whose bone marrow had been
reconstituted with a single HSC35. Considering the results
from their observation of an enormous number of
Lethal irradiation LacZ mice
BMT
Atherosclerotic lesion in aorta
X-gal X-gal  α-SMA
ApoE/ mice
Figure 3. Bone marrow-derived progenitor cells are detected in atherosclerotic plaque. The bone marrow of 8-week-old
ApoE−/− mice is reconstituted with that of ROSA-26 mice (BMTLacZApoE−/− mice). The recipient mice are fed a western type
diet for 8 weeks, starting at 4 weeks after bone marrow transplantation (BMT). A significant amount of LacZ-positive cells is
detected in the atherosclerotic plaques of the BMTLacZApoE−/− mice by X-gal staining. Some of them expressed α-smooth mus-
cle actin (α-SMA). A = atheroma; M = media. Bar = 50 µm. Reproduced with permission from the Nature Publishing Company.
sections, the authors concluded that transdifferentiation
of HSCs into other lineages is an extremely rare event35.
This apparent discrepancy could merely be derived from
the analysis of noninjured vs. injured tissues in the two
studies from the contribution of other cell types in the
KSL fraction. A recent study on ischemic myocardium
failed to detect any contribution of hematopoietic cells
toward cardiac, smooth muscle, or endothelial pheno-
type36. We investigated the vascular lesion induced by
wire after the bone marrow was reconstituted by a sin-
gle HSC37. Although a single HSC showed an apprecia-
ble level of hematopoietic engraftment activity, very
few cells in the lesion were derived from a single HSC.
Our result suggests that it is a rare property for a
highly purified HSC to transdifferentiate into vascular
cells, whereas the KSL fraction of bone marrow cells
contains a distinct population that could substantially
contribute to lesion formation. Although the KSL frac-
tion is considered to be enriched with HSCs33, mes-
enchymal stem cells or other multipotent cells that are
more primitive than HSCs38 could also be included in
this fraction. It is plausible that those nonhematopoi-
etic cells in the KSL fraction might be responsible for
the KSL-derived endothelial-like cells or smooth mus-
cle-like cells observed in the vascular lesion3.
Cell Surface Markers for EPCs
EPCs have been well studied with regard to their char-
acteristics, molecular phenotypes, and the processes
leading to their mobilization from the bone marrow and
homing to sites of neovascularization39. Initially, human
EPCs were considered to be included in the CD34 and/or
AC133 (also called CD133) positive fraction of periph-
eral mononuclear cells (MNCs)1. Then, it was reported
that endothelial-like cells can outgrow from nonpurified
total MNCs on fibronectin-coated dish in the presence
of vascular endothelial growth factor (VEGF), express
Bandeiraea simplicifolia (BS)-lectin, and have the capacity
of acetylated low density lipoprotein (LDL) uptake40.
However, it takes more than 4 days until the plated
MNCs make clusters for the assay, and the BS-lectin +
acetylated LDL uptake + fraction of MNCs contains het-
erogeneous cells. It was reported that endothelial-like
cells could arise from both CD14 + and CD14− MNCs41.
Thus, the number of acetylated LDL +BS-lectin+ cells
may not be the best indicator for the estimation of the
number of functional EPCs in systemic circulation.
Therefore, many investigators tried to find a better
marker to identify circulating vascular progenitors.
Several cell surface markers, including CD3442, CD34+
CD45−43, CD34+VEGFR-2+44, and VEGFR-2+AC133+44,
were frequently used to quantify the number of circu-
lating EPCs. However, it was reported that CD34− mes-
enchymal bone marrow cells45 and CD34-B220-CD3−
VEGFR-2+ HSC population in peripheral blood46 can
differentiate into ECs45, and another group reported that
CD34−CD133+VEGFR-2+ EPC is a precursor of CD34+
CD133+VEGFR-2+ EPC, functionally more potent than
these with respect to homing and vascular repair47.
Others reported that VEGFR-1 on EPCs is more important
for angiogenesis than VEGFR-248. It was also reported 
that murine EPCs express VEGFR-2 and vascular
endothelial-cadherin49.
It still remains unclear how highly “EPCs” can differ-
entiate into mature ECs phenotypically and function-
ally50. Identification of pure and real EPCs is expected.
Moreover, standardization of cell markers to identify
putative EPCs is valuable to compare the number of
circulating EPCs in patients from different institutes.
Markers of Smooth Muscle Progenitor Cells
The molecular mechanism of mobilization, homing,
and differentiation of putative smooth muscle progen-
itors still remains unclear. There were few papers that
described the phenotype of putative smooth muscle
progenitor cells51. It still remains unclear whether
endothelial-like cells or smooth muscle-like cells differ-
entiate from a common vascular progenitor. Deb et al.
reported that smooth muscle progenitors had high
expression of β1 integrin, moderate expression of α1,
and low levels of α(v)β3, and did not express α(v)β5,
β2, α2β1, or α4β1 integrins52. In contrast, endothelial
progenitors had high expression of α2β1, α(v)β3,
α(v)β5, β1, and α1 and minimal expression of α4β1.
The authors suggested the potential importance of inte-
grins in mediating adherence of smooth muscle pro-
genitors to specific extracellular matrix both in vitro and
in vivo. Given the diversity of smooth muscle-like cells
observed in human lesions53, it is likely that there are
heterogeneous sources of smooth muscle-like cells54.
Future studies will identify the source of smooth muscle
progenitors and the molecular signaling that dictates
the recruitment of smooth muscle progenitors at the
site of vascular repair and lesion formation51,55.
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Cell Fusion as a Possible Mechanism of
Bone Marrow-derived Vascular Cells
Many animal experiments have indicated that adult stem
cells can transdifferentiate into other lineages31,56–58.
On the other hand, recent papers suggested that adult
stem cells can adopt a tissue-specific phenotype by cell
fusion in vitro59,60 and in vivo61,62, but not by transdif-
ferentiation. It is possible that cell fusion can account
for, at least in part, the accumulation of bone marrow-
derived SMC-like cells in vascular lesions4. Consistent
with this notion, previous reports documented poly-
ploidization of vascular SMCs in response to mechani-
cal and humoral stimuli63. However, spontaneous cell
fusion between recipient and donor-derived cells
appeared to be a very rare event in a murine model of
cardiac transplantation between LacZ and GFP mice64.
Thus, it is likely that circulating progenitors can express
vascular cell markers with and without cell fusion like
putative cardiac progenitors65.
Therapeutic Strategies Targeting Circulating
Smooth Muscle Progenitor Cells
Recent findings indicate that bone marrow-derived
smooth muscle progenitor cells might represent an
additional target for the treatment to prevent vascular
diseases4. Consistent with this notion is the observa-
tion that transient myelosuppression can inhibit SMC
hyperplasia in balloon-injured coronary arteries66.
Inhibition of chemokine10 or adhesion molecule11 also
effected to reduce neointimal formation after vascular
injury.
The implantation of coronary stents has been shown
to reduce the risk of periprocedural complications and
restenosis more than does balloon angioplasty alone67.
However, in-stent restenosis (ISR) remains a significant
clinical problem limiting the long-term success of per-
cutaneous treatment. The principal cause is the exces-
sive accumulation of SMCs. Recently, sirolimus-eluting
stent (SES) has emerged as a promising strategy to pre-
vent ISR. Sirolimus is a hydrophoric macrolide with
immunosuppressive activity. A randomized, double-
blind trial demonstrated that the use of SES reduced the
rates of restenosis and clinical events even in patients
with complex lesions68, and the beneficial effect per-
sisted for at least 3 years69. Despite increasing clinical
interest in SES, the mechanism of locally delivered
sirolimus to prevent ISR still remains undetermined70.
Recently, we reported that sirolimus potently inhibits
differentiation of human vascular progenitor cells71.
The potent inhibitory effects of sirolimus on circulating
smooth muscle progenitor cells may, at least in part,
mediate the clinical efficacy of SES. On the other hand,
sirolimus may potentially affect re-endothelialization
after stent implantation, causing late thrombosis after
interruption of antiplatelet therapy72.
It may be possible to develop gene therapies to
vascular diseases that target vascular progenitor cells.
One potential approach could involve the Fas/Fas ligand
(FasL) system73,74. Fas is a death receptor that transmits
an apoptosis-inducing signal when its ligand, FasL, is
activated75,76. Overexpression of FasL inhibited infiltra-
tion of inflammatory cells and reduced neointimal
formation after vascular injury77–79. FasL induces apop-
tosis in Fas-bearing vascular SMC77, while ECs are
refractive to FasL overexpression77,80,81. Thus, FasL over-
expression induces apoptotic cell death of SMCs and
reduces lesion formation, while re-endothelialization
at this same site would not be inhibited77,82. Moreover,
local delivery of FasL should be predicted to kill bone
marrow-derived progenitor cells as well as inflamma-
tory cells at these lesions because these cells express
Fas79,80. It was also reported that cell surface overex-
pression of FasL in ECs by transgenic approach attenu-
ated homing of hematopoietic cells in a model of
rodent transplant vasculopathy78. These vessels also
displayed reduced neointimal formation78. It is conceiv-
able that EC-specific overexpression of FasL inhibits
transplant arteriosclerosis by preventing accumula-
tion of smooth muscle progenitors, at least in part.
Therapeutic Application of Bone 
Marrow-derived Progenitor Cells for
Vascular Disease
There is increasing enthusiasm for the use of adult stem
cells for “cell transplantation therapy” and “tissue
engineering”83,84. It was reported that chronic treatment
with bone marrow-derived progenitor cells from young
nonatherosclerotic ApoE−/− mice prevented atheroscle-
rosis progression in ApoE−/− recipients despite persistent
hypercholesterolemia, presumably by facilitating
re-endothelialization on recipient arteries in areas at
risk for atherosclerotic injury43. However, given the
pluripotency of adult stem cells, they may potentially
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differentiate into unfavorable cell types. In fact, simi-
larities between stem and cancer cells have been sug-
gested85. Studies in animal models have shown that
somatic stem cells participate in pathologic remodeling
in remote organs86,87. Thus, we should pay attention to
potential adverse effects as well as beneficial aspects
caused by the transplanted stem cells in the clinic.
The effects and safety of therapeutic angiogenesis by
bone marrow cell transplantation for ischemic limbs88
or ischemic heart disease89–91 have been described in
many papers. Initially, it was suggested that the func-
tional prevention was caused by corporation of bone
marrow cells to formation of new vessels in the
ischemic tissues. However, recently, it has been con-
sidered that the more critical function of transplanted
bone marrow cells to angiogenesis is the paracrine
release of proangiogenic factors, not transdifferentiation
to ECs92–95.
As mentioned above, bone marrow-derived progen-
itor cells are also associated with pathologic angiogene-
sis or atherosclerotic lesion formation (Figure 4). A recent
clinical trial with myocardial infarction patients showed
that granulocyte colony-stimulating factor mobilization
of stem cells and subsequent infusion of such cells
improved cardiac performance and angiogenesis96.
However, this improvement was associated with an
unexpectedly high rate of ISR, which led to premature
termination of the trial. Similarly, bone marrow-derived
MNCs have been shown to accelerate atherosclerosis
in ApoE−/− mice97.
Apart from these few studies, almost all the other
clinical trials did not report any negative effects, such as
pathologic angiogenesis or acceleration of atheroscle-
rosis. Three papers about bone marrow cell therapy for
acute myocardial infarction (AMI) were published98–100.
In these papers, bone marrow cells were infused intra-
coronarily after successful percutaneous intervention
in AMI patients, and contractile function of the left 
ventricle (LV) was observed after 3 months98, 4 months99,
6 months100, and 1 year99. Two of these studies sug-
gested the improvement of LV contraction by bone
marrow cell infusion98,99, but the other one failed to
provide the effect. None of them detected unfavorable
effects, which might be caused by transplantation of
bone marrow-derived cells. However, the safety of
BMT should be monitored for a longer time.
It is expected that the mechanistic clarity of the













Figure 4. Potential contribution of bone marrow-derived progenitors to physiologic (GOOD) and pathologic (BAD) conditions.
Bone marrow-derived progenitors contribute to physiologic vascular repair in injured vessels and collateral formation in
ischemic tissues. Bone marrow-derived progenitor cells may also participate in atherosclerotic lesion formation and pathologic
angiogenesis including tumor angiogenesis, vasa vasorum formation in atherosclerotic lesion, retinopathy, rheumatoid
arteritis, and psoriasis.
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cell transplantation will be elucidated before these
strategies are applied to a wide range of patients with
ischemic disease2. Moreover, it would be important to
transplant appropriate fractions of progenitors at opti-
mal doses for regenerative medicine, and differentiation
and localization of transplanted progenitors should be
monitored to prevent unfavorable outcomes.
In summary, current findings indicate that bone
marrow cells can contribute not only to the healing
process of injured arterial wall, but also to pathologic
vascular remodeling. These findings may provide the
basis for the development of new therapeutic strate-
gies for vascular disease that involve targeting the
mobilization, homing, differentiation, and proliferation
of bone marrow-derived vascular progenitor cells. Bone
marrow cells will also be a useful therapeutic tool for
ischemic diseases, but unexpected effects may occur.
Therefore, further experiments that dissect the molec-
ular mechanisms by which progenitors are recruited
and differentiated at the site of injury are warranted.
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